Kuros Biosciences Yönetim

Yönetim kriter kontrolleri 2/4

Kuros Biosciences' CEO'su Chris Fair, Oct2023 tarihinde atandı, in görev süresi bir yıldan az. in toplam yıllık tazminatı CHF 1.34M olup, şirket hissesi ve opsiyonları dahil olmak üzere 24.6% maaş ve 75.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.36% ine doğrudan sahiptir ve bu hisseler CHF 2.34M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1 yıl ve 6.1 yıldır.

Anahtar bilgiler

Chris Fair

İcra Kurulu Başkanı

CHF 1.3m

Toplam tazminat

CEO maaş yüzdesi24.6%
CEO görev süresiless than a year
CEO sahipliği0.4%
Yönetim ortalama görev süresiless than a year
Yönetim Kurulu ortalama görev süresi6.1yrs

Son yönetim güncellemeleri

Shareholders May Find It Hard To Justify Increasing Kuros Biosciences AG's (VTX:KURN) CEO Compensation For Now

Apr 12
Shareholders May Find It Hard To Justify Increasing Kuros Biosciences AG's (VTX:KURN) CEO Compensation For Now

What We Learned About Kuros Biosciences' (VTX:KURN) CEO Pay

Nov 17
What We Learned About Kuros Biosciences' (VTX:KURN) CEO Pay

Recent updates

Kuros Biosciences AG's (VTX:KURN) Shares Climb 30% But Its Business Is Yet to Catch Up

Oct 24
Kuros Biosciences AG's (VTX:KURN) Shares Climb 30% But Its Business Is Yet to Catch Up

Market Participants Recognise Kuros Biosciences AG's (VTX:KURN) Revenues Pushing Shares 37% Higher

Aug 22
Market Participants Recognise Kuros Biosciences AG's (VTX:KURN) Revenues Pushing Shares 37% Higher

We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth

Jul 16
We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth

Kuros Biosciences AG (VTX:KURN) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable

May 30
Kuros Biosciences AG (VTX:KURN) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable

Why Investors Shouldn't Be Surprised By Kuros Biosciences AG's (VTX:KURN) 35% Share Price Surge

Apr 11
Why Investors Shouldn't Be Surprised By Kuros Biosciences AG's (VTX:KURN) 35% Share Price Surge

Some Confidence Is Lacking In Kuros Biosciences AG (VTX:KURN) As Shares Slide 29%

Jan 03
Some Confidence Is Lacking In Kuros Biosciences AG (VTX:KURN) As Shares Slide 29%

Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth

Dec 17
Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth

We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth

Sep 17
We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth

Market Cool On Kuros Biosciences AG's (VTX:KURN) Revenues

Jun 28
Market Cool On Kuros Biosciences AG's (VTX:KURN) Revenues

Here's Why We're Not At All Concerned With Kuros Biosciences' (VTX:KURN) Cash Burn Situation

May 03
Here's Why We're Not At All Concerned With Kuros Biosciences' (VTX:KURN) Cash Burn Situation

Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth

Jun 11
Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth

Shareholders May Find It Hard To Justify Increasing Kuros Biosciences AG's (VTX:KURN) CEO Compensation For Now

Apr 12
Shareholders May Find It Hard To Justify Increasing Kuros Biosciences AG's (VTX:KURN) CEO Compensation For Now

Reflecting on Kuros Biosciences' (VTX:KURN) Share Price Returns Over The Last Five Years

Mar 02
Reflecting on Kuros Biosciences' (VTX:KURN) Share Price Returns Over The Last Five Years

What We Learned About Kuros Biosciences' (VTX:KURN) CEO Pay

Nov 17
What We Learned About Kuros Biosciences' (VTX:KURN) CEO Pay

CEO Tazminat Analizi

Chris Fair'un ücretlendirmesi Kuros Biosciences'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-CHF 9m

Mar 31 2024n/an/a

-CHF 11m

Dec 31 2023CHF 1mCHF 329k

-CHF 14m

Sep 30 2023n/an/a

-CHF 15m

Jun 30 2023n/an/a

-CHF 16m

Mar 31 2023n/an/a

-CHF 15m

Dec 31 2022CHF 36kn/a

-CHF 15m

Sep 30 2022n/an/a

-CHF 13m

Jun 30 2022n/an/a

-CHF 11m

Mar 31 2022n/an/a

-CHF 9m

Dec 31 2021CHF 36kn/a

-CHF 8m

Tazminat ve Piyasa: Chris 'ın toplam tazminatı ($USD 1.58M ) Swiss pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 1.53M ).

Tazminat ve Kazançlar: Chris şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.


CEO

Chris Fair (54 yo)

less than a year

Görev süresi

CHF 1,337,700

Tazminat

Mr. Christopher T. Fair, also known as Chris, serves as the Chief Executive Officer At Kuros Biosciences AG since October 2023 and serves as Director since April 17, 2024. He was the Chief Operating Office...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Christopher Fair
CEO & Directorless than a yearCHF 1.34m0.36%
CHF 3.2m
Daniel Geiger
Chief Financial Officer1.4yrsVeri yokVeri yok
Sjoerd Musters
COO & GM of BVless than a yearVeri yokVeri yok
Joost de Bruijn
President of Innovation and Strategy & Executive Directorless than a yearCHF 873.70kVeri yok
G. Ross
Senior Vice President of Marketing & Business Developmentless than a yearVeri yokVeri yok
Nikki Coleman
Vice President of Global Human Resourcesless than a yearVeri yokVeri yok
Philippe Saudan
Chief Development Officer8.2yrsVeri yokVeri yok
John Griffin
Chief Commercial Officer6.5yrsVeri yokVeri yok
Katherine Sage
Senior Vice President of Medical & Clinical Affairsless than a yearVeri yokVeri yok
Virginia Jamieson
Consultant6.4yrsVeri yokVeri yok

1.0yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: KURN 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1 yıl), bu da yeni bir ekibin varlığını gösteriyor.


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Christopher Fair
CEO & Directorless than a yearCHF 1.34m0.36%
CHF 3.2m
Joost de Bruijn
President of Innovation and Strategy & Executive Director6.3yrsCHF 873.70kVeri yok
Clemens van Blitterswijk
Chairman7.3yrsCHF 92.60k1.95%
CHF 17.7m
Oliver Walker
Independent Non-Executive Director6.3yrsCHF 73.80kVeri yok
Cato Laurentin
Member of Advisory Boardno dataVeri yokVeri yok
Ralph Müller
Member of Advisory Boardno dataVeri yokVeri yok
Norbert Boos
Member of Advisory Boardno dataVeri yokVeri yok
Thomas Steffen
Member of Advisory Boardno dataVeri yokVeri yok
Andrew Sama
Member of Strategic Advisory Board6.1yrsVeri yokVeri yok
Richard Allen
Member of Strategic Advisory Board6.1yrsVeri yokVeri yok
Alpesh Patel
Member of Strategic Advisory Board6.1yrsVeri yokVeri yok
Kornelis Poelstra
Member of Strategic Advisory Board6.1yrsVeri yokVeri yok

6.1yrs

Ortalama Görev Süresi

56.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: KURN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.1 yıldır).